Clinical trials: Healthy Adolescents
Infections, Meningococcal
The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination
The purpose of this study is to evaluate the long-term antibody persistence 6, 7, 8, 9 and 10 years after receiving a primary vaccination of meningococcal conjugate vaccine MenACWY-TT versus Meningitec™ or Mencevax™ ACWY, and the…
- Trial name
- NCT01962207
- Testing
- Meningococcal vaccine GSK134612
- Where
- 9 sites in Finland
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07660198
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 77 sites in United States, Finland and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Substance-related Disorders, Alcohol-Related Disorders
LaunchPad: Supporting Healthy Decisions and Preventing Drug Use After High School
LaunchPad is an online substance use prevention program for high school seniors. The program is designed to help seniors develop skills and make informed decisions as they transition from high school to young adulthood.
- Conditions
- Substance-related Disorders, Alcohol-Related Disorders, Tobacco Use Disorder, Marijuana Use
- Trial name
- NCT07655609
- Testing
- Introduction, Norms re: Protective Behavior Strategies (PBS), Life Skills
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Prevention Strategies, LLC
Influenza
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
Flublok was studied previously in children 6 -59 months of age and demonstrated less than satisfactory immunogenicity results, especially in the 6-36 month age group.
- Trial name
- NCT01959945
- Testing
- Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old
This protocol is designed to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine licensed in the EU and many other worldwide…
- Trial name
- NCT00464672
- Testing
- Influenza virus vaccine, Comparator influenza vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Novartis
Dengue Fever
Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315…
- Trial name
- NCT03999996
- Testing
- Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
- Where
- 10 sites in United States, Mexico
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Takeda
Infections, Papillomavirus
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of…
- Trial name
- NCT00534638
- Testing
- Cervarix, Engerix-B
- Where
- 6 sites in Finland
- Volunteers
- 34,412 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chikungunya Virus Infection
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination
The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate…
- Trial name
- NCT06007183
- Testing
- CHIKV VLP vaccine booster
- Where
- 24 sites in United States
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Smoking Cessation
A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers
This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.
- Trial name
- NCT00463918
- Testing
- varenicline
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningococcal Immunisation, Healthy Volunteers
Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants
Primary Objective: To describe the safety profile of the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines in healthy adults, adolescents, toddlers and infants, when administered alone (Stages 1-4) or…
- Trial name
- NCT04825223
- Testing
- Multicomponent Meningococcal B Vaccine, Meningococcal Group B Vaccine MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 576 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
The aim of the study is to document immunogenicity and safety of VRVg in a pre-exposure regimen in healthy children and adolescents aged 2 to 17 years.
- Trial name
- NCT01930357
- Testing
- Purified Vero Rabies Vaccine Serum Free (VRVg), Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),
- Where
- 2 sites in Philippines
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Vaccine
A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years
This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how well it is tolerated.
- Trial name
- NCT01299480
- Testing
- Vaccine
- Where
- 63 sites in Czechia, Denmark and 5 more
- Volunteers
- 1,714 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningococcal Vaccine, rLP2086
A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.
This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how it is tolerated when given together with Repevax.
- Conditions
- Meningococcal Vaccine, rLP2086, Repevax, N Meningitidis Serogroup B
- Trial name
- NCT01323270
- Testing
- rLP2086, Repevax, Saline
- Where
- 36 sites in Finland, Germany and 1 more
- Volunteers
- 753 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neoplasms, Glandular and Epithelial, Diphtheria
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
Data from this study are expected to demonstrate that Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine), when administered concomitantly with a combined diphtheria, tetanus, pertussis, and…
- Conditions
- Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough
- Trial name
- NCT00337428
- Testing
- Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF), Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF), Comparator: REPEVAX™ (Concomitant)
- Volunteers
- 843 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Seasonal Influenza
Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age
This study will evaluate the safety and immunogenicity in healthy children and adolescents after one or two IM dose(s) of trivalent subunit inactivated flu vaccine.
- Trial name
- NCT01209780
- Testing
- TIV, TIVf, Comparator TIV
- Where
- 13 sites in Colombia, Mexico and 2 more
- Volunteers
- 3,116 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Avian
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents
The purpose of this study is to assess the safety and immunogenicity (i.e. primary immune response, immunogenicity of two different doses, antibody persistence 360 days after the first vaccination, immune response to a…
- Trial name
- NCT01052402
- Testing
- H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
- Where
- 20 sites in Australia, Finland and 2 more
- Volunteers
- 684 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Infections, Meningococcal
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds
The purpose of the observer-blinded study is to determine the immunogenicity and safety of one dose of GlaxoSmithKline (GSK) Biologicals' meningococcal vaccine GSK 134612 compared to one dose of Mencevax™ ACWY in healthy subjects…
- Trial name
- NCT01154088
- Testing
- Mencevax ACWY, GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]
- Where
- 3 sites in Panama, Philippines and 1 more
- Volunteers
- 1,170 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Tolerance and Safety of an Oral Nutritional Supplement
This is an open label, non-randomized, interventional, single arm study.
- Trial name
- NCT05100901
- Testing
- MAG oil oral nutritional supplement (ONS)
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Influenza, Human
Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents
The purpose of this study is to evaluate the immunogenicity and safety of 'IL-YANG Quadrivalent Seasonal Influenza Vaccine' in healthy Korean children and adolescents.
- Trial name
- NCT03445468
- Testing
- IL-YANG Quadrivalent Influenza Vaccine, IL-YANG Flu Vaccine Pre-filled Syringe
- Where
- South Korea
- Volunteers
- 379 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Infections, Meningococcal
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in adolescents/adults 11-25 years of age.
- Trial name
- NCT00454909
- Testing
- Meningococcal vaccine 134612, Menactra®
- Where
- 10 sites in United States
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline